Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats

xlomafota13 shared this article with you from Inoreader Telmisartan inhibits bladder smooth muscle fibrosis in neurogenic bladder rats Via Experimental and therapeutic medicine Exp Ther Med. 2022 Mar;23(3):216. doi: 10.3892/etm.2022.11140. Epub 2022 Jan 11. ABSTRACT Hypertension is associated with bladder symptoms. The present study investigated whether an angiotensin receptor blocker could improve the symptoms and pathological changes associated with a neurogenic bladder (NB). A Sprague-Dawley rat model of NB was constructed. Rats in the sham and model groups were gavaged with saline, and rats in the treatment group were gavaged with telmisartan. Urodynamic parameters, including maximum cystometric capacity, residual urine volume, bladder wet weight, bladder compliance and detrusor pressure, were detected. Masson and H&E staining were performed to assess bladder fibrosis and histopathological changes. The expression levels of basic fibroblast growth factor (bFGF), TGF-β1, Collagen I, Collagen III, and α-smooth muscle actin (α-SMA) were also measured by reverse transcription-quantitative PCR, western b lotting and immunohistochemistry. The model rats exhibited symptoms and pathological changes associated with NB. Treatment with telmisartan reduced maximum cystometric capacity, residual urine volume, bladder compliance and bladder wet weight, and increased detrusor pressure in model rats. The tissue staining results showed that telmisartan exerted an antifibrotic effect. In addition, telmisartan inhibited the expression of bFGF, TGF-β1, Collagen I, Collagen III and α-SMA in model rats. Therefore, the results of the present study indicated that telmisartan may serve as a potential therapeutic agent for NB. PMID:35126719 | PMC:PMC8796288 | DOI:10.3892/etm.2022.11140 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.